Checkpoint inhibitors have transformed cancer treatment over the past decade, helping hundreds of thousands of patients by ...

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, ...

Recently, the Insilico team's research entitled "An Internal Sulfur-Lone Pair Interaction Enabled the Discovery of Potential and Sub-Family Selective PKMYT1 Inhibitors" was invited for publication as ...

Using rapid protein degradation, chemogenomics, and super‑resolution microscopy in mouse embryonic stem cells, the team dissected the distinct contributions of BRD2 and BRD4 to transcription.

Nuvalent seeks FDA approval of neladalkib for TKI-pretreated advanced ALK-positive NSCLC, leveraging ALKOVE-1 results demonstrating activity in extracranial disease and brain metastases. ALKOVE-1 ...

For over a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations.

Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...

A new research paper was published in Volume 17 of Oncotarget on March 31, 2026, titled “Efficacy and safety of PD-1/ PD-L1 ...

Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.

Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they’ve often fallen short. New ...